Stocks Stumble on Growth Worries Aug 18, 2009
Gilead Sciences () announced that it has received a subpoena from the Office of the Inspector General of the Dept. of Health and Human Services requesting documents regarding the development, marketing and sales of Ranexa. Ranexa is approved for the treatment of chronic angina and was developed and originally commercialized by CV Therapeutics, a company that Gilead acquired in April 2009. (BusinessWeek)
Stock questions? Ask Matt Aug 17, 2009
Stock market's 'Lost Decade' wasn't a loss for these stocks - USATODAY.com. Stock market's 'Lost Decade' wasn't a loss for these stocks. (USA Today -- Money)
Gilead Sciences Announces Colorado Closures Aug 13, 2009
Gilead Sciences announces closure of offices in Boulder, Westminster ... Gilead Sciences Inc., a biopharmaceutical firm known for its HIV therapies, is closing its offices in Boulder and Westminster and laying off at least 66 people by year's end. (ABC News -- Wire)
Makers of Tamiflu version see share prices surge Aug 13, 2009
US-based Gilead Sciences drug Tamiflu (generic name oseltamivir phosphate) is the most widely used medicine to treat swine flu. Swiss company Roche has the marketing license for the drug. (India Times)
Alcoholic Rats Show Kudzu May Help Addicted Humans Aug 13, 2009
Though kudzu extract is already available in health food stores, "it's not a good drug," said study leader Ivan Diamond, vice president of Gilead Sciences, a biopharmaceutical company that is working to develop a kudzu-based compound for humans. That's because kudzu extract unregulated by the U.S. Food and Drug Administration is poorly absorbed by the body and its concentration varies wildly from bottle to bottle, he said. (National Geographic)
Drugs Work Best When Swine Flu Found Early Jul 29, 2009
These include zanamivir, made by GlaxoSmithKline under license from Biota Inc. and sold under the brand name Relenza, and oseltamivir, made by Roche AG under license from Gilead Sciences and sold under the brand name Tamiflu. Both drugs can reduce the risk of death among people at serious risk of flu complications -- the very old, the very young, people with asthma and other chronic diseases and pregnant women. (MEDLINEplus)
First Defense Against Swine Flu - Seasonal Vaccine Jul 28, 2009
Schuchat advised against summer camps offering the antiviral drug oseltamivir -- Roche AG and Gilead Sciences Inc's Tamiflu -- to prevent infection among children. "At this point we're strongly recommending them for treatment rather than for prevention," she said. (MEDLINEplus)
Swine flu spreads to remote corners of world Jul 28, 2009
Drugmakers Roche, Gilead Sciences and GlaxoSmithKline have benefited from a worldwide rush to secure supplies of their antiviral drugs to fight the spreading flu. Vaccine makers including Sanofi-Aventis, Novartis NOVN.VX, Baxter and Solvay are also working on H1N1 shots that could be given alongside seasonal flu jabs. (MSNBC -- Health)
Swine Flu Spreads; Health Officials Plan Vaccines Jul 28, 2009
Schuchat advised against summer camps offering the antiviral drug oseltamivir -- Roche AG and Gilead Sciences Inc's Tamiflu -- to prevent infection among children. The drugs should be reserved for people at high risk of complications who have been in close contact with a known case, she said. (MEDLINEplus)
IMMUNISING KIDS Jul 26, 2009
Reuters AlertNet - First defense against swine flu - seasonal vaccine. Sun, 04:36 26 Jul 2009 GMT. (AlertNet)
GLOBAL IMPACT Jul 26, 2009
Reuters AlertNet - Swine flu spreads; health officials plan vaccines. Sun, 04:32 26 Jul 2009 GMT. (AlertNet)
Newsweek: The next blockbuster drugs Jul 23, 2009
The Potential Blockbusters: Although some concerns have been raised about its side effects, especially at high doses, the up-and-coming candidate to watch for high blood pressure is a biopharmaceutical from Gilead Sciences Inc. called Darusentan. In May, the company announced data from one of its two Phase III clinical trials of the candidate in patients with resistant hypertension. (MSNBC -- Health)
Analyst Picks and Pans: Las Vegas Sands, Gilead, Intl. Paper Jul 22, 2009
Gilead Sciences Inc. () ... Gilead Sciences Inc. is expected to report another quarter of revenue and profit growth on July 21, with key HIV treatments Atripla and Truvada again leading the way. (BusinessWeek)
Actelion Raises Sales, Profit Forecasts as Net Climbs on Tracleer Revenue Jul 21, 2009
Tracleer faces competition from Gilead Sciences Inc.s Letairis, which won approval in 2007. The Foster City, California-based company acquired the medicine, also known as Volibris, through its 2006 takeover of Myogen Inc.. (Bloomberg -- Europe)
Stocks Cap Week With Big Gains Jul 18, 2009
Gilead Sciences Inc (Added 07/06/2009). . (Investors Business Daily)
Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences Jul 17, 2009
CORK, Ireland, July 16 /PRNewswire/ --Tibotec Pharmaceuticals today announced that it has entered into a license and collaboration agreement with Gilead Sciences, Inc. for the development and commercialization of a new once-daily fixed-dose antiretroviral product containing Tibotec's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride 25 mg) and Gilead's Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for treatment-naive... (PR Newswire)
Behind a Cooley Star's Long Goodbye Jul 11, 2009
Both did huge deals for clients that had grown up at the firm, such as Gilead Sciences Inc., and companies that came to Cooley just for the dealmakers themselves, like eBay. At the same time, the startup practice is much less profitable than the dealmaking. (Law.com)
OSI Pharmaceuticals to shut Boulder office Jul 9, 2009
OSI acquired its Boulder site in 2001 when it bought the Boulder-based oncology unit of Gilead Sciences, formerly NeXstar Pharmaceuticals. OSI s main drug is the cancer treatment Tarceva, which accounted for more than 80 percent of the company s $379. (Denver Business Journal, CO)
Cooley Corporate Stars Switching to Dewey Jul 8, 2009
Climan was a Dealmaker of the Week earlier this year after advising Gilead Sciences Inc. in its $1. 4 billion acquisition of CV Therapeutics Inc. His recent big deals also included Brocade Communications Systems' $3 billion acquisition of Foundry Networks Inc. Reifschneider led Cooley's team in Qualcomm Inc.'s $891 settlement of patent litigation earlier this year. (Law.com)
Marcial: Achillion, a Promising Biotech Jun 29, 2009
The maker of antiviral and antibacterial treatments is hunting for big partners, similar to its agreement with Gilead Sciences, to test and produce new products ... Although the company is tiny and unprofitable, its research and products under development have lured some big pharmaceutical companies such as Gilead Sciences (). (BusinessWeek)
AIDS/LifeCycle 8 to Raise $10.5 Million to Fight AIDS Jun 1, 2009
AIDS/LifeCycle's presenting sponsors are Shopoff Properties Trust, FedEx Corporation, and Gilead Sciences. In April 2009, the Kaiser Family Foundation released survey findings that showed that only 6 percent of Americans call HIV/AIDS the most urgent health problem facing the nation, down from 44 percent in 1995; see. (PR Newswire)
U.S. Officials Consider Bumping Up Flu Shot Season May 22, 2009
Tamiflu, or oseltamivir, is made by Roche AG and Gilead Sciences Inc while the inhaled drug Relenza, or zanamivir, is made by GlaxoSmithKline and Biota Inc.. The new flu seems to be about as contagious as seasonal flu, Jernigan said. (MEDLINEplus)
Early Use Of Antiretroviral Treatment Improves Survival Rate Of HIV Patients May 18, 2009
The drugs for the study were supplied by Abbott Laboratories (lopinavir/ritonavir) and Gilead Sciences (tenafovir and emtricitabine). The patients in the early arm of the study were treated with ARVs within an average of 12 days, while those in the deferred group received the treatment within an average of 45 days. (Science Daily)
Sodium channel blocker shows promise as a potential treatment for cystic fibrosis May 18, 2009
Currently, GS-9411 is in Phase I clinical trials being conducted by Parion's development partner, Gilead Sciences, Inc., in Foster City, CA.. During the study, researchers applied GS-9411 to airway surface cells grown in the laboratory, and assessed the potency and reversibility of the drug on these cells. (EurekAlert!)
AIDS patients with serious complications benefit from early retroviral use, Stanford study shows May 16, 2009
The drugs for the study were supplied by Abbott Laboratories (lopinavir/ritonavir), Gilead Sciences (tenofovir and emtricitabine) and Bristol-Myers Squibb (stavudine). The patients in the early intervention arm of the study were treated with ARVs within an average of 12 days, while those in the deferred group received the treatment within an average of 45 days after the start of treatment for the opportunistic infection. (EurekAlert!)
Gilead sues Teva over patents again May 16, 2009
-based Gilead (NASDAQ:GILD) said the patents at issue are associated with emtricitabine, a component of HIV drugs Truvada and of Atripla, and are licensed exclusively to Gilead Sciences by. The lawsuit is based on an abbreviated new drug application filed by Teva (NASDAQ:TEVA) that seeks approval to manufacture and market a generic version of Atripla before the expiration of both emtricitabine patents. (Philadelphia Business Journal, PA)
Gilead files 2nd patent suit against Teva May 16, 2009
The Foster City-based company (NASDAQ:GILD) said the patents at issue are associated with emtricitabine, a component of Truvada and of Atripla, and are licensed exclusively to Gilead Sciences by Emory University. The lawsuit is based on an Abbreviated New Drug Application filed by Teva Pharmaceuticals USA Inc., which seeks approval to manufacture and market a generic version of Atripla before the expiration of both emtricitabine patents. (San Jose Business Journal, CA)
Health authorities prepare to limit flu drug use May 13, 2009
Swiss drugmaker Roche AG, which makes Tamiflu under license from Gilead Sciences Inc., said it would donate 5. 65 million packets to WHO to replenish stockpiles deployed against the H1N1 outbreak. (The Star Online, Malaysia)
This Rally Is Righteous! May 10, 2009
Metric(s) systemA pair of aces quickly make that cut: IBM (NYSE: IBM) and Gilead Sciences (Nasdaq: GILD), each of which has generates loads of FCF. The honchos in charge have been highly effective stewards as well, wringing out double-digit profitability as measured by ROE. 10% or higher is a good absolute hurdle for that metric, one these companies have consistently cleared. More critical, though, is how a firm has fared relative to likeminded rivals. (MSNBC -- Business)
Growth in All the Wrong Places May 9, 2009
Royalties in and of themselves aren't bad -- Gilead Sciences (Nasdaq: GILD) gets them from Roche for Tamiflu and royalties have become an integral strategy for OSI Pharmaceuticals (Nasdaq: OSIP), which receives them from Roche for ex-U.S. sales of Tarceva and for patents that cover diabetes drugs made by Merck (NYSE: MRK), Novartis (NYSE: NVS), and Bristol-Myers Squibb (NYSE: BMY). But clearly Onyx would prefer growth to come from places where it gets a higher portion of sales. (MSNBC -- Business)
Swine Flu Kills Second Person in U.S. May 7, 2009
4 million treatment courses of Roche AG's and Gilead Sciences Inc's Tamiflu, an antiviral proven effective against the new flu, to 72 nations, including Mexico. Fukuda said the WHO was still trying to answer the most pressing questions, including why more people have died in Mexico than anywhere else. (MEDLINEplus)
Flu virus kills Texas woman, more cases expected May 6, 2009
4 million treatment courses of Roche AG's and Gilead Sciences Inc's Tamiflu, an antiviral proven effective against the new flu, to 72 nations. CHINESE HEAD HOME. (Yahoo News -- Top Stories)
"Eye on Entertainment" Conducts Interviews on the Red Carpet at the 2009 Los Angeles Asian Pacific Film Festival May 3, 2009
Sponsors of the Los Angeles Asian Pacific Film Festival 25th Anniversary include: Official Vehicle Sponsor - Toyota; Premiere - Directors Guild of America, Gilead Sciences; Gold - Verizon Wireless; Official Beer Sponsor - Stella Artois; Official Domestic Airlines - Southwest Airlines; Government Support - City of Los Angeles Department of Cultural Affairs, Los Angeles County Arts Commission, National Endowment for the Arts; Media Sponsors - , KPCC, LA Weekly, and LA18. The Los Angeles Asian... (Yahoo News -- Press Releases)
> Local businesses, hospitals say they're ready to tackle flu May 1, 2009
Foster City-based Gilead Sciences Inc., which discovered Tamiflu, licensed worldwide commercialization rights to Roche and receives royalties for the drug. Gilead does not manufacture or distribute the drug, but its closing price on April 29 was up at $46. (San Jose Business Journal, CA)
Gator surprises Fla. woman planning test drive Apr 30, 2009
Alligator surprises Fla. woman planning test drive. (San Francisco Chronicle -- Weird News)
Mumbai attacks, floods on agenda as India votes Apr 30, 2009
By RAJESH SHAH, Associated Press Writer. Thursday, April 30, 2009. (San Francisco Chronicle -- Politics)
Glaxo 1Q profit drops 13 percent Apr 30, 2009
With 11 HIV medicines already on sale, the new venture will have a 19 percent market share, ranking it No. 2 behind sales leader Gilead Sciences Inc. Other competitors in the field include heavyweights Bristol-Myers Squibb Co., Abbott Laboratories, Merck & Co. and DuPont Pharmaceuticals Co.. Attempts to boost Glaxo's line-up of consumer healthcare products include the launch of its non-prescription weight-loss drug alli in pharmacies across Europe earlier this week. (Yahoo News -- Pharmaceutical Industry News)
Report: Pharma deals in 1Q exceed all 2008 deals Apr 30, 2009
8 billion, including debt, and Gilead Sciences Inc. buying CV Therapeutics Inc. for $1. 4 billion. (Yahoo News -- Pharmaceutical Industry News)
WHO raises swine flu threat level Apr 30, 2009
Two antiviral drugs -- Relenza, made by GlaxoSmithKline and Tamiflu, made by Roche AG and Gilead Sciences Inc. -- have been shown to work against the H1N1 strain. Drugmakers have donated millions of doses of their drugs to the WHO. She also alerted governments to be ready to distribute stockpiles of their drugs. (India Times, India)
Guzman update Apr 30, 2009
" Violet Blue. Coming to a nuclear arsenal near you! Mark Fiore. Sean Penn files for separation; see who is expecting twins. BofA shareholders oust Ken Lewis as chairman over Merrill purchase. Sony will reportedly unveil its next-gen PSP at June's E3 conference. Aspiring dancers audition at Radio City Music Hall. Annoying things they do. How they can stop. Tim Goodman. Sorry, Chicago-style snobs, the prez's favorite slice is from S.F. Is it dangerous to 'friend' everyone you ever knew? FromRed... (San Francisco Chronicle -- Sports)
Network shows waiting to hear the verdict for fall Apr 30, 2009
By FRAZIER MOORE, AP Television Writer. Wednesday, April 29, 2009. (San Francisco Chronicle -- Entertainment)
WHO raises flu threat level, warns pandemic imminent Apr 30, 2009
Thu, 07:42 30 Apr 2009 GMT. (For full coverage of the flu outbreak, click [nFLU]). (AlertNet)
Firms Look to Prevent Swine Flu Pandemic, Turn a Profit Apr 29, 2009
Companies gearing up for swine flu, including Roche, Gilead Sciences and GlaxoSmithKline, the manufacturers of the leading antiviral flu medications, are best positioned to see a boost in profits if the disease escalates to epidemic proportions, analysts said. Tamiflu, which comes in pills, was developed by Gilead and manufactured by Roche. (ABC News -- Business)
Flu's bad news but shot in the arm for biotech Apr 29, 2009
Among the few notable exceptions to the Dow's generally down day on Monday was Foster City's Gilead Sciences Inc., which climbed nearly 4 percent to close at $47. 53. (San Francisco Chronicle)
Swine flu fears increasingU.S. declares public health emergency Apr 29, 2009
" If you're over 40, you've seen the "swine flu" routine before. It came out of the blue. The government created hysteria over it and tried to herd everyone into mandatory vaccinations. The vaccinations killed and disabled numerous people before they were discontinued. Below is a link to a video with some material about ANOTHER government/media created hysteria-hoax, avian bird flu. The mechanics are exactly the same. This video starts slow, but is worth watching and studying. The Devil is in... (Klamath Falls Herald & News, OR)
US stocks down on swine flu worries Apr 28, 2009
56, and Gilead Sciences Inc. rose 3. 8 percent, climbing $1. (The Star Online, Malaysia)
Pandemic casts a pall across global prospects Apr 28, 2009
Gilead Sciences Inc., which developed Tamiflu and receives royalties from Roche, rose 4 percent. Not all countries have significant stockpiles of the Tamiflu and Relenza. (MSNBC -- Business)
Glaxo, Novavax, other drug stocks leap due to swine flu Apr 28, 2009
He covers Gilead Sciences, which developed Tamiflu and gets royalties from Roche. The outbreak "raises the awareness that these threats still do exist," he says. (USA Today -- News)
Flu's bad news but shot in the arm for biotech Apr 28, 2009
Among the few notable exceptions to the Dow's generally down day on Monday was Foster City's Gilead Sciences Inc., which climbed nearly 4 percent to close at $47 ... Flu's bad news but shot in the arm for biotech Articles Among the few notable exceptions to the Dow's generally down day on Monday was Foster City's Gilead Sciences Inc. , which climbed nearly 4 percent to close at $47. (San Francisco Chronicle -- Business)
Drugmaker Shares Rise on Swine-Flu Outbreak Apr 28, 2009
Gilead Sciences Inc., Roche, GlaxoSmithKline and other companies with a stake in flu treatments and detection will likely see revenue boosts if the swine flu outbreak continues to spread, several Wall Street analysts said. The bug is already suspected in more than 100 deaths in Mexico, with more than 1,400 cases, mostly in Mexico City. (ABC News -- Wire)
Report: Pharma deals in 1Q exceed all 2008 deals Apr 28, 2009
8 billion, including debt, and Gilead Sciences Inc. buying CV Therapeutics Inc. for $1. 4 billion. (Yahoo News -- Pharmaceutical Industry News)
Drug and Vaccine Makers on Standby Over Swine Flu Apr 28, 2009
Tamiflu was originally invented by U.S. biotech company Gilead Sciences Inc, while Relenza was licensed to Glaxo by Australia's Biota Holdings Ltd.. The longer-term battle against any pandemic, however, depends not on antiviral drugs but a successful vaccine. (MEDLINEplus)
Glaxo 1Q profit drops 13 percent Apr 28, 2009
With 11 HIV medicines already on sale, the new venture will have a 19 percent market share, ranking it No. 2 behind sales leader Gilead Sciences Inc. Other competitors in the field include heavyweights Bristol-Myers Squibb Co., Abbott Laboratories, Merck & Co. and DuPont Pharmaceuticals Co.. Attempts to boost Glaxo's line-up of consumer healthcare products include the launch of its non-prescription weight-loss drug alli in pharmacies across Europe earlier this week. (Yahoo News -- Pharmaceutical Industry News)
Roche scales up production of flu cure Apr 28, 2009
Tamiflu, or oseltamivir, is given as a convenient tablet, and was originally invented by US biotech company Gilead Sciences Inc. Reuters. Most Viewed. (The Star Online, Malaysia -- Business)
Business Briefing Apr 20, 2009
-- Earnings reports expected from Advanced Micro Devices, Delta Air Lines, Gilead Sciences, Merck, SanDisk, Seagate Technology, UAL, Yahoo. W. (San Francisco Chronicle -- Business)
They turned Half Moon Bay into home Apr 20, 2009
The Grassler family had to move from North Carolina when Frank, who works for Gilead Sciences, was relocated to the firm's offices in Foster City. Holt, his wife, said the company's relocation specialist took them on a whirlwind tour of 11 Bay Area cities. (San Francisco Chronicle)
Bay Area companies ride out the storm Apr 19, 2009
The top 10 most profitable companies are almost the same as the top revenue producers, except that instead of McKesson and Safeway, Gilead Sciences and eBay join the top tier. As with revenue, those top 10 profitmakers account for the lion's share - with a twist. (San Francisco Chronicle -- Business)
Glaxo and Pfizer create new HIV drug company Apr 17, 2009
With 11 HIV medicines already on sale, the new venture will have a 19 percent market share, just behind leader Gilead Sciences Inc. Other competitors include Bristol-Myers Squibb Co., Abbott Laboratories, Merck & Co. and DuPont Pharmaceuticals Co.. "The combination of a broad current revenue base and a new diverse pool of pipeline assets provides a significant platform to invest in developing and delivering new HIV medicines," Glaxo Chief Executive Andrew Witty told analysts during a conference... (NJ.com -- News)
U.S. Still Holds Keys To Drive Innovation, Despite Challenges Apr 11, 2009
Gilead Sciences (GILD), a steady grower since it became profitable in 2002, was among the long list of stocks that took a plunge on the. 03/05/2009 06:10 PM ET. (Investors Business Daily)
Screen Center Apr 4, 2009
4/3/2009 (Market Close) Indexes refresh every two minutes. eIBD Investor's Business Daily Digital Edition. (Investors Business Daily)
Archives: Gilead Sciences
